Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study

Bendamustine + rituximab (BR) has demonstrated high response rates in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). However, progression-free survival (PFS) after BR is <18 months. This study was designed to determine if maintenance lenalidomid...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Br J Haematol
Auteurs principaux: Chang, Julie E., Havighurst, Thomas, Kim, KyungMann, Eickhoff, Jens, Traynor, Anne M., Kirby-Slimp, Rachel, Volk, Lynn M., Werndli, Jae, Go, Ronald S., Weiss, Matthias, Blank, Jules, Kahl, Brad S.
Format: Artigo
Langue:Inglês
Publié: 2016
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5923897/
https://ncbi.nlm.nih.gov/pubmed/26913697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13957
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires